Mianserin

NERVOUS SYSTEM

Key facts

Mianserin is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1976. DrugCentral lists 57 molecular targets, including Adra1a, HRH1 and HRH1. Recorded indications include Major depressive disorder.

• Molecular targets: Adra1a, HRH1, HRH1 and Htr2c|Htr2a|Htr2b (57 listed in DrugCentral).
• Indications: Major depressive disorder.
• ATC code: N06AX03 (Other antidepressants).
• Molecular formula: C18H20N2; molecular weight 264.37 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Major depressive disorder

Mechanism & targets

Molecular targets (57)

Target	Gene	Action	Activity
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 10.15
Histamine H1 receptor	HRH1	unknown	Ki 9.24
Histamine H1 receptor	HRH1	unknown	Ki 9.07
Serotonin 2 (5-HT2) receptor	Htr2c|Htr2a|Htr2b	unknown	Ki 8.96
5-hydroxytryptamine receptor 2C	Htr2c	unknown	Ki 8.85
5-hydroxytryptamine receptor 2A	Htr2a	unknown	Ki 8.82
5-hydroxytryptamine receptor 2C	HTR2C	antagonist	Ki 8.52
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 8.42
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 8.32
5-hydroxytryptamine receptor 1B	Htr1b	antagonist	Ki 8.30
Cerebral cortex alpha adrenergic receptor	ADRA1A|ADRA2A	unknown	IC50 8.22
5-hydroxytryptamine receptor 2A	HTR2A	antagonist	Ki 8.17
5-hydroxytryptamine receptor 2B	HTR2B	antagonist	Ki 8.12
5-hydroxytryptamine receptor 1F	HTR1F	unknown	Ki 8.06
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 7.77
Transporter	Slc6a2	unknown	Ki 7.59
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 7.57
5-hydroxytryptamine receptor 1B	HTR1B	unknown	Ki 7.53
Alpha-1D adrenergic receptor	ADRA1D	antagonist	Ki 7.50
Alpha-1B adrenergic receptor	ADRA1B	antagonist	Ki 7.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
N06AX03	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Coma	402.2
Drug interaction	267.5
Poisoning deliberate	265.3
Somnolence	241.5
Hepatocellular injury	215.6
Agranulocytosis	210.6
Altered state of consciousness	187.7
Drug abuse	179.2
Hyponatraemia	177.2
Cholestasis	173.0
Fall	172.7
Cerebral artery thrombosis	170.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Mianserin is on its molecule page.

• Molecular formula: C₁₈H₂₀N₂
• Molecular weight: 264.37 g/mol
• CAS number: 24219-97-4
• InChIKey: UEQUQVLFIPOEMF-UHFFFAOYSA-N
• PubChem CID: 4184

CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mianserin used for?

DrugCentral lists the following indications for Mianserin: Major depressive disorder.

How does Mianserin work?

Its molecular targets in DrugCentral include Adra1a, HRH1, HRH1 and Htr2c|Htr2a|Htr2b.

When was Mianserin first approved?

Mianserin was first approved by the YEAR INTRODUCED in 1976.

What is the chemical formula of Mianserin?

Mianserin has the molecular formula C18H20N2 and a molecular weight of 264.37 g/mol.

Sources

• DrugCentral drug card 1796 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL544428 — compound record and bioactivity
• PubChem CID 4184 — chemical identifiers
• DrugBank DB06148 — drug record
• FDA UNII 250PJI13LM — substance identity
• UniProt P35367 (HRH1) — target protein
• UniProt P28335 (HTR2C) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt P28223 (HTR2A) — target protein
• UniProt P41595 (HTR2B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.